Alercell Inc. – Trademark Portfolio
Entity Type: 03
Alercell Inc. holds 9 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 5 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 4 Nice Classification classes. Currently, 8 trademarks are registered and 1 is pending. Notable registered marks include LENA S1, ALERCELL, LENA Q51, LENA CODE, and LENA SCORE. The owner is based in Bozeman, MT.
5 W Mendenhall St Suite 202
Bozeman, MT 59715
Showing of trademarks Trademarks
Trademark Classifications
Alercell Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Alercell Inc. have?
Alercell Inc. has 9 U.S. trademarks filed with the USPTO. Of these, 8 registered, 1 pending.
What trademark classes does Alercell Inc. file in?
Alercell Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Alercell Inc.'s most well-known trademarks?
Alercell Inc.'s registered trademark portfolio includes well-known marks such as LENA S1, ALERCELL, LENA Q51, LENA CODE, and LENA SCORE. These are among 8 currently registered trademarks in the portfolio.
What is Alercell Inc.'s trademark registration success rate?
Alercell Inc. has a 100% trademark registration rate, with 8 out of 8 resolved applications resulting in successful registration. Currently, 1 application is pending review.